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1Vascular calcification (VC) increases progressively during aging and associated with higher risks for any cardio-
vascular event and mortality.1–4 Diverse pathologies including 
chronic kidney disease, diabetes mellitus, atherosclerosis, as 
well as chronic respiratory diseases are associated with accel-
erated calcification.5–8
Osteochondrogenic differentiation of vascular smooth 
muscle cells (VSMCs) is considered to be the key event in 
VC.9,10 Upon osteochondrogenic differentiation, VSMCs 
upregulate master transcription factors of osteogenesis and 
chondrogenesis, such as RUNX2 (runt-related transcription 
factor 2) and SOX9 (Sry-related HMG box-9); parallel with 
this process, they lose VSMC lineage markers such as smooth 
muscle actin α-2.9–13 RUNX2, SOX9, and their target genes 
such as ALP (alkaline phosphatase) and OCN (osteocalcin) 
are found to be upregulated in calcifying vascular tissues.9–13 
Several inducers and inhibitors of such transdifferentiation 
have been identified to date.14–17
Accumulating evidence suggests a link between hypoxia 
and accelerated calcification. For example, arterial calcifica-
tion is increased in patients with asthma, chronic obstructive 
pulmonary disease, and obstructive sleep apnea,6–8 but whether 
hypoxia plays a contributory role in triggering arterial calcifi-
cation in these conditions has not been addressed.
HIF-1 (hypoxia-inducible factor 1) pathway is the master 
regulator of cellular and systemic homeostatic response to 
hypoxia. The HIF-1 pathway is regulated by the oxygen-sen-
sitive α subunit (HIF-1α) that is stabilized upon hypoxia.18 
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Objective—Vascular calcification is associated with high risk of cardiovascular events and mortality. Osteochondrogenic 
differentiation of vascular smooth muscle cells (VSMCs) is the major cellular mechanism underlying vascular calcification. 
Because tissue hypoxia is a common denominator in vascular calcification, we investigated whether hypoxia per se 
triggers osteochondrogenic differentiation of VSMCs.
Approach and Results—We studied osteochondrogenic differentiation of human aorta VSMCs cultured under normoxic 
(21% O2) and hypoxic (5% O2) conditions. Hypoxia increased protein expression of HIF (hypoxia-inducible factor)-1α 
and its target genes GLUT1 (glucose transporter 1) and VEGFA (vascular endothelial growth factor A) and induced mRNA 
and protein expressions of osteochondrogenic markers, that is, RUNX2 (runt-related transcription factor 2), SOX9 (Sry-
related HMG box-9), OCN (osteocalcin) and ALP (alkaline phosphatase), and induced a time-dependent calcification of 
the extracellular matrix of VSMCs. HIF-1 inhibition by chetomin abrogated the effect of hypoxia on osteochondrogenic 
markers and abolished extracellular matrix calcification. Hypoxia triggered the production of reactive oxygen species, 
which was inhibited by chetomin. Scavenging reactive oxygen species by N-acetyl cysteine attenuated hypoxia-mediated 
upregulation of HIF-1α, RUNX2, and OCN protein expressions and inhibited extracellular matrix calcification, which 
effect was mimicked by a specific hydrogen peroxide scavenger sodium pyruvate and a mitochondrial reactive oxygen 
species inhibitor rotenone. Ex vivo culture of mice aorta under hypoxic conditions triggered calcification which was 
inhibited by chetomin and N-acetyl cysteine. In vivo hypoxia exposure (10% O2) increased RUNX2 mRNA levels in mice 
lung and the aorta.
Conclusions—Hypoxia contributes to vascular calcification through the induction of osteochondrogenic differentiation of 
VSMCs in an HIF-1–dependent and mitochondria-derived reactive oxygen species–dependent manner.  (Arterioscler 
Thromb Vasc Biol. 2019;39:00-00. DOI: 10.1161/ATVBAHA.119.312509.)
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Some studies associated HIF-1α levels and VC. For example, 
a positive correlation between plasma HIF-1α levels and ar-
terial calcification has been shown in patients with type 2 di-
abetes mellitus.19 In addition, a study revealed that HIF-1α 
colocalizes with neoangiogenesis and areas of calcification in 
stenotic valves.20
Recently, a direct role of HIF-1 activation has been shown 
in phosphate-induced VSMC calcification that could be rel-
evant in mineral imbalance-induced calcification in patients 
with chronic kidney disease.21 Moreover, pulmonary arte-
rial hypertension was found to be associated with increased 
pulmonary arterial calcification and elevated expression of 
RUNX2 in the lungs of patients with pulmonary arterial hy-
pertension.22 These works proposed that sustained RUNX2 
expression promotes HIF-1α activation and that RUNX2/HIF-
1α axis triggers proliferative and osteogenic phenotype switch 
of VSMCs.21,22
Hypoxia triggers adaptation mechanisms, including but 
not limited to angiogenesis, vascular reactivity and remod-
eling and metabolic alterations such as upregulation of glu-
cose uptake and glycolysis to foster survival in a low oxygen 
condition.23 As part of the hypoxic response, cells reduce ox-
ygen consumption of mitochondria through the upregulation 
of pyruvate dehydrogenase kinase 1 that leads to inactivation 
of pyruvate dehydrogenase which prevents the conversion of 
pyruvate to acetyl-CoA and thus attenuates the entry of pyru-
vate to the mitochondrial Krebs cycle.24
It is generally accepted that intracellular reactive oxygen 
species (ROS) levels also change during hypoxia, but the di-
rection of this change and the origin of ROS (mitochondrial 
or NADPH oxidase) remained controversial.25 Because ROS 
production requires oxygen one might assume that ROS pro-
duction is attenuated in hypoxia which idea is supported by 
several studies.25 On the other hand, accumulating evidence 
suggests that hypoxia-mediated partial inhibition of the mito-
chondrial electron transport chain is associated with increased 
mitochondrial ROS production.26–30 Recent evidence sug-
gests that upon hypoxia mitochondria-derived elevated ROS 
production stabilizes HIF-1α; and therefore, elevated ROS 
production plays a critical role in hypoxia-driven cellular 
responses.29–31
Unfettered ROS production has been implicated in cardi-
ovascular pathophysiology including VC.32 Elevated ROS for-
mation was detected in animal models of VC and in human 
sclerotic and stenotic aortic valves.33 Vascular cells expressing 
osteogenic markers were identified as a source of excess ROS, 
and in vitro studies revealed that ROS production is enhanced 
during osteogenic differentiation of VSMCs.33 A recent study 
showed that inhibition of mitochondrial ROS generation 
attenuates phosphate-mediated osteogenic differentiation of 
VSMCs, suggesting a causative role of ROS in VC.34 Because 
hypoxia is a common feature in diverse pathologies when car-
diovascular calcification occurs, here we investigated the role 
of hypoxia, HIF-1 activation, and ROS formation in osteo-
chondrogenic differentiation of human aortic SMCs.
Materials and Methods
The article adheres to the implementation of the Transparency and 
Openness Promotion Guidelines. The data that support the findings of 
this study are available from the corresponding author upon request.
Materials
Unless specified otherwise, reagents were from Sigma-Aldrich Co 
(St Louis, MO).
Mice
All experiments were performed in compliance with institutional 
(Institutional Ethics Committee, University of Debrecen) and na-
tional guidelines. Twenty-four C57BL/6 mice (8–10 weeks old, male 
and female, sex matched) were randomly divided into 4 groups. Mice 
were housed in cages with standard bedding and unlimited access to 
food and water placed into transparent gas-tight acrylic chambers. 
The hypoxia group obtained a premade gas mixture of 10% O2 and 
90% of N2 (Messer Group GmbH, Bad Soden, Germany). The nor-
moxia group obtained a premade gas mixture of 21% O2 and 79% of 
N2 (Messer Group GmbH). The total gas flow through the chamber 
was adjusted to 5 to 10 L/min. Temperature was maintained at 24°C 
to 26°C, and a standard light-dark cycle of ≈12-hour light exposure 
was used. At the indicated time of hypoxia exposure (12, 24, and 48 
hours), mice were sacrificed with CO2 inhalation and perfused with 
5 mL of ice-cold Dulbecco’s PBS (DPBS; D8537; Sigma). Aorta and 
lung samples were collected, snap-frozen in liquid N2, and kept at 
−80°C until analysis.
Cell Culture and Reagents
Human aorta VSMCs (354-05; Cell Applications Inc, San Diego, 
CA) were maintained in DMEM (D6171; Sigma) supplemented with 
10% FBS (F2442; Sigma), antibiotic-antimycotic solution (A5955; 
Sigma), and l-glutamine (G7513; Sigma). Cells were maintained 
at 37°C in a humidified atmosphere containing 5% CO2. Cells were 
grown to confluence and used from passages 5 to 8. Experiments 
were performed on 2 cell lines derived from different donors. In some 
experiments, we cultured VSMCs in osteogenic medium that was 
obtained by supplementing the growth medium with inorganic phos-
phate (NaH2PO4-Na2HPO4, pH 7.4, 2.5 mmol/L; S5011 and S5136; 
Sigma) and CaCl2 (0.6 mmol/L; C8106; Sigma).
Hypoxic Treatment
Hypoxic condition was obtained by placing the cells into a modular 
incubator chamber (Billups-Rothenberg Inc, Del Mar, CA), which 
was connected to a gas bottle containing a mixture of 5% O2, 5% 
Nonstandard Abbreviations and Acronyms
ALP alkaline phosphatase
BRD4 bromodomain protein 4
DPBS Dulbecco’s PBS
ECM extracellular matrix
GLUT1 glucose transporter protein type 1
HIF-1 hypoxia-inducible factor 1
NAC N-acetyl cysteine
OCN osteocalcin
OD optical density
ROS reactive oxygen species
RUNX2 runt-related transcription factor 2
SOX9 Sry-related HMG box-9
SP sodium pyruvate
VC vascular calcification
VEGFA vascular endothelial growth factor A
VSMC vascular smooth muscle cell
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CO2, and 94% of N2 (Messer Group GmbH). A continuous slow flow (0.1 L/min) was applied throughout the experiment. To obtain nor-
moxia, we used a gas mixture of 21% O2, 5% CO2, and 74% of N2. 
In some experiments, we used hypoxia mimetic drugs CoCl2 (CC, 
200 μmol/L; 60818; Sigma), desferrioxamine (20 μmol/L; D9533; 
Sigma), 2, 2′-bipyridyl (100 μmol/L; D216305; Sigma), or the HIF-1 
inhibitor chetomin (6 nmol/L; C9623; Sigma).
Alizarin Red Staining and Quantification
Alizarin red staining was performed as described previously.35 In 
brief, after washing with DPBS, the cells were fixed in 4% parafor-
maldehyde (16005; Sigma) and rinsed with deionized water thor-
oughly. Cells were stained with Alizarin Red S (A5533; Sigma) 
solution (2%, pH 4.2) for 20 minutes at room temperature. Excessive 
dye was removed by several washes in deionized water. To quantify 
alizarin red staining in 96-well plates, we added 100 μL of hexadecy-
lpyridinium chloride (C9002; Sigma) solution (100 mmol/L) to the 
wells and measured optical density (OD) with a spectrophotometer 
(Hitachi U-2800A) at 560 nm using hexadecylpyridinium chloride 
solution as blank.
Determination of Cell Viability
Cell viability was determined by the 3-[4, 5-Dimethylthiazol-2-yl]-
2,5-diphenyl-tetrazolium bromide assay as previously described.36 In 
brief, cells were cultured and treated in 96-well plates for the indi-
cated time. Then cells were washed with DPBS, and 100 μL of 3-[4, 
5-Dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (0.5 mg/
mL; M2128; Sigma) solution in DPBS was added. After a 4-hour in-
cubation, the 3-[4, 5-Dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium 
bromide solution was removed, formazan crystals were dissolved in 
100 μL of DMSO (D8779; Sigma), and OD was measured with a 
spectrophotometer (Hitachi U-2800A) at 570 nm using DMSO as 
blank. Viability of nontreated cells at day 0 was considered as 100%, 
whereas viability of cells treated with 1% Triton X-100 (X100; 
Sigma) was considered as 0%. We used the following equation to 
calculate viability of samples: viability of sample=[OD570
sample/(OD570Day0 Ctrl−OD570Triton x-100)]×100.
ALP Activity Assay
Cells grown in 96-well plates were washed with DPBS twice, sol-
ubilized with 1% Triton X-100 in 0.9% NaCl (S7653; Sigma) and 
assayed for ALP activity. In brief, 130 μL of Alkaline Phosphatase 
Yellow Liquid Substrate (P7998; Sigma) was combined with 50 μg of 
protein samples, incubated at 37°C for 30 min, and then the kinetics 
of p-nitrophenol formation was followed for 30 minutes at 405 nm. 
Maximum slope of the kinetic curves was used for calculation.
Quantification of Ca Deposition
Cells grown on 96-well plates were washed twice with DPBS and 
decalcified with HCl (30721; Sigma; 0.6 mol/L) for 30 minutes at 
room temperature. Ca content of the HCl supernatants was deter-
mined by QuantiChrom Calcium Assay Kit (DICA-500; Gentaur, 
Kampenhout, Belgium) as previously described.37 Following decal-
cification, cells were washed twice with DPBS and solubilized with 
a solution of NaOH (S8045; Sigma; 0.1 mol/L) and sodium dodecyl 
sulfate (20760; Sigma; 0.1%), and protein content of samples were 
measured with BCA protein assay kit (23225; Pierce Biotechnology, 
Rockford, IL). Ca content of the cells was normalized to protein con-
tent and expressed as μg/mg protein.
Quantitative Reverse Transcription 
Polymerase Chain Reaction
RNA was isolated from cells using Trizol (CS502, RNA-STAT60; 
Tel-Test Inc, Friendswood, TX) according to the manufacturer’s pro-
tocol. Two micrograms of RNA was reverse transcribed to cDNA with 
High-Capacity cDNA Reverse Transcription Kit (4368813; Applied 
Biosystems, Waltham, MA). Quantitative real-time polymerase chain 
reaction was performed using iTaq Universal Probes Supermix (172–
5134; BioRad Laboratories, Hercules, CA) and predesigned prim-
ers and probes (TaqMan Gene Expression Assays) to detect VEGFA 
(Hs.00900055), GLUT1 (Hs.00892681), RUNX2 (Hs.535845), 
SOX9 (Hs.1001343), MSX2 (Hs.00741177), ALP (Hs.00768162), 
OCN (Hs.01587814), GAPDH (Hs.02758991), and Cyclophilin A 
(Hs04194521). Relative mRNA expressions were calculated with the 
ΔΔCt method using GAPDH or CyPA as internal control.
Western Blot Analysis
We evaluated HIF-1α, Glut-1, RUNX2, SOX9, and ALP protein 
expressions in whole cell lysates. Proteins (20 μg/lane) were resolved 
on 10% SDS-PAGE, then blotted onto a nitrocellulose membrane 
(Amersham Proton 1060003; GE Healthcare, Chicago, IL). Western 
Blotting was performed with the use of an anti–HIF-1α antibody 
(GTX30647; GeneTex, Irvine, CA) at a 1 μg/mL concentration, anti–
Glut-1 antibody (GTX15309; GeneTex) at a 0.5 μg/mL concentra-
tion, anti-RUNX2 antibody (20700-1-AP; Proteintech, Rosemont, 
IL) at 0.2 μg/mL concentration, anti-SOX9 antibody (ab184547; 
Abcam, Cambridge, United Kingdom) at 1 μg/mL concentration, and 
anti-ALP antibody (sc-30203; Santa Cruz Biotechnology, Inc, Dallas, 
TX) at 1 μg/mL concentration. After the binding of the primary anti-
bodies, membranes were incubated with Amersham ECL Rabbit 
IgG, HRP-linked whole Ab (NA-934; GE Healthcare) at 0.5 μg/mL 
concentration. Antigen-antibody complexes were visualized with 
Amersham ECL Western Blotting Detection Reagent (RPN2109; GE 
Healthcare). After detection, the membranes were stripped and rep-
robed for β-actin with the use of an anti–β-actin antibody (sc-47778; 
Santa Cruz Biotechnology, Inc) at a concentration of 0.5 μg/mL. 
Results were quantified by using Alpha DigiDoc RT (Alpha Innotech, 
San Leandro, CA).
Quantification of OCN
For OCN detection, the extracellular matrix (ECM) of cells grown on 
6-well plates was dissolved in 100 μL of EDTA (E6758; Sigma; 0.5 
mol/L, pH 6.9). Concentration of OCN was quantified by an ELISA 
(BMS2020INST; eBioscience, San Diego, CA) using 25 μL of the 
EDTA-solubilized ECM samples.
Intracellular ROS Measurement
ROS production was monitored by using the 5-(and-6)-chloromethyl-
2′,7′-dichlorodihydro-fluorescein di-acetate, acetyl ester assay 
(C6827; Life Technologies, Carlsbad, CA) as previously described.38 
After a 4-hour pretreatment, cells were washed with DPBS and loaded 
with 5-(and-6)-chloromethyl-2′,7′-dichlorodihydro-fluorescein di-
acetate, acetyl ester (10 μmol/L, 30 minutes, in the dark). Cells were 
washed thoroughly with DPBS, and fluorescence intensity was meas-
ured in every 30 minutes for 4 hours applying 488 nm excitation and 
533 nm emission wavelengths. In some experiments, we applied ROS 
inhibitors during the hypoxia treatment, N-acetyl cysteine (NAC, 1 
mmol/L; A9165; Sigma), Mn(III)-tetrakis (4-benzoic acid) porphyrin 
chloride (50 μmol/L; sc-221954; Santa Cruz Biotechnology, Inc), so-
dium pyruvate (SP, 5 mmol/L; P5280; Sigma), GKT137831 (GKT, 20 
μmol/L; HY-12298; MedChem Express, Sollentuna, Sweden), and 
rotenone (5 μmol/L; R8875; Sigma).
Aorta Organ Culture Model and 
Quantification of Ca
C57BL/6 mice (N=35 in total, N=5 per group) were sacrificed with 
CO2 inhalation and perfused with 5 mL of ice-cold DPBS. Entire 
aortas were harvested and cleaned using a dissecting microscope 
under aseptic conditions. Aortas were maintained in DMEM (D6171; 
Sigma) supplemented with 10% FBS (F2442; Sigma), antibiotic-
antimycotic solution (A5955; Sigma), and l-glutamine (G7513; 
Sigma) under hypoxic (5% O2) or normoxic conditions for 6 days. 
As positive control, we used osteogenic medium that was obtained 
by supplementing the basal culture medium with inorganic phosphate 
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(NaH2PO4-Na2HPO4, pH 7.4, 2.5 mmol/L) as previously described.39 
In some experiments, we applied NAC (5 mmol/L) and chetomin (6 
nmol/L) during the hypoxia treatment. The medium was replaced in 
every other day. After 6 days of treatment, aortas were opened lon-
gitudinally and decalcified with 50 μL of HCl (30721; Sigma; 0.6 
mol/L) for 30 minutes at room temperature. Ca content of the HCl 
supernatants was determined by QuantiChrom Calcium Assay Kit 
(DICA-500; Gentaur, Kampenhout, Belgium) and normalized to the 
wet weight of the aortas.
Statistical Analysis
Results are expressed as mean±SD. At least 3 independent experi-
ments were performed for all in vitro studies. Statistical analyses were 
performed with GraphPad Prism software (version 8.01, San Diego, 
CA). Shapiro-Wilk test was performed to assess normality of distri-
bution. All data passed normality and equal variance tests; therefore, 
parametric tests were used to determine P values. Statistically sig-
nificant differences between 2 groups were assessed using a 2-tailed 
Student t test. Comparisons between >2 groups were performed by 
1-way ANOVA followed by Tukey multiple comparisons test. To 
compare each of a number of treatment groups with a single control 
group, we performed 1-way ANOVA followed by Dunnett post hoc 
test. Because of low mice number/group, data from male and female 
mice were analyzed together in the ex vivo and in vivo experiments. 
A value of P <0.05 was considered significant.
Results
Hypoxia Induces Osteochondrogenic Differentiation 
and ECM Mineralization of VSMCs
To investigate whether hypoxia plays a role in osteochondro-
genic reprogramming of human VSMCs first we investigated 
whether hypoxia (5% O2) or the hypoxia mimetics CoCl2 
(200 μmol/L), desferrioxamine (20 μmol/L) and 2,2′-bipyri-
dyl (100 μmol/L) trigger stabilization of HIF-1α in VSMCs. 
After 12 hours of treatment, we evaluated protein expression 
of HIF-1α from whole cell lysate (Figure 1A). We found that 
hypoxia as well as all the hypoxia mimetics increased HIF-1α 
levels markedly (≈5- to 8-fold) in VSMCs. Because GLUT1 
(glucose transporter 1) and VEGFA (vascular endothelial 
growth factor A) are regulated by the HIF-1 pathway next 
we evaluated protein expressions of GLUT1 and VEGFA. 
Hypoxia and hypoxia mimetics increased GLUT1 expres-
sion (12 hours) and VEGFA secretion (48 hours) in VSMCs 
(Figure 1A and 1B). Parallel with these changes, hypoxia (5% 
O2, 6 hours) caused a 2- to 3-fold elevation of mRNAs encod-
ing osteochondrogenic transcription factors, that is, RUNX2, 
SOX9, and Msh Homeobox 2 (MSX2; Figure 1C). Moreover, 
we found that mRNA levels of OCN and ALP, genes under the 
control of the osteochondrogenic transcription factors, were 
also elevated in VSMCs exposed to hypoxia (1.52±0.04 fold 
and 1.8±0.08 fold increases over normoxia controls, respec-
tively; Figure 1C).
Next, we evaluated protein expressions of RUNX2, 
SOX9, and ALP in VSMCs exposed to normoxia or hypoxia 
for 12 hours, 3 days, and 6 days. Compared with normoxia 
controls, expressions of RUNX2 and SOX9 were elevated at 
12 hours and 6 days (Figure 1D). Protein expression as well 
as enzyme activity of ALP was increased after 6 days of hy-
poxia exposure (Figure 1D and 1E). Next, we have measured 
the level of OCN, a major noncollagenous protein in miner-
alized bone, in the ECM of VSMCs in every 5 days for 20 
days. Concentration of OCN was low and did not change in 
VSMCs under normoxia (Figure 1F). In contrast, hypoxia 
triggered a time-dependent elevation of OCN levels in the 
ECM (days 15 and 20).
To study whether the observed hypoxia-induced lineage 
reprogramming of VSMCs leads to ECM calcification, we 
exposed VSMCs to hypoxia for 10 days and measured Ca 
deposition in the ECM. As a positive control, we used oste-
ogenic medium that was supplemented with phosphate (2.5 
mmol/L) and Ca (0.6 mmol/L), that is a well-established in-
ducer of ECM calcification in VSMCs. Hypoxia triggered 
time-dependent Ca accumulation in the ECM although the 
calcification was delayed and weaker compared with phos-
phate-mediated Ca deposition (Figure 2A). This result was 
confirmed by alizarin red staining, which showed weak pos-
itivity following a 10-day hypoxia exposure (Figure 2B). 
These results suggest that hypoxia per se acts as an osteo-
genic factor in VC in vitro.
Calcification of VSMCs has been associated with apop-
totic cell death especially in high phosphate and calcium con-
ditions10; therefore, next we investigated whether cell death 
could play a role in hypoxia-induced ECM calcification in 
VSMCs. We exposed VSMCs to hypoxia or osteogenic me-
dium and measured cell viability after 10 days of treatment. 
None of the treatments influenced cell viability that remained 
higher than 90% after 10 days of treatment when compared 
with cell viability determined on day 0 (Figure 2C).
Hypoxia Triggers Osteochondrogenic 
Differentiation of VSMC Through HIF-1
In general, hypoxia-induced cellular responses are medi-
ated via HIF-1. To test whether HIF-1 activation is involved 
in hypoxia-mediated osteochondrogenic differentiation of 
VSMCs we applied chetomin, a well-characterized and se-
lective inhibitor of HIF-1 transcriptional activity. First, we 
checked the efficiency of chetomin in inhibiting HIF-1 ac-
tivity by evaluating mRNA levels and protein expressions of 
VEGFA and GLUT1. In response to hypoxia (5% O2, 6 hours) 
VSMCs upregulated both VEGFA and GLUT1 transcriptions 
which responses were completely abolished in the presence 
of chetomin (Figure 3A). Then we evaluated the level of 
VEGFA in supernatant of VSMCs cultured under hypoxic 
conditions in the presence or absence of chetomin for 48 hours 
(Figure 3B). Chetomin inhibited hypoxia-mediated upregula-
tion of VEGFA formation (Figure 3B). In addition, we found 
that chetomin attenuated the increase in GLUT1 protein ex-
pression triggered by hypoxia (5% O2, 12 hours; Figure 3C).
Next we investigated the effect of chetomin on hypoxia-
induced upregulation of osteochondrogenic markers. In the 
presence of chetomin hypoxia-induced increase in RUNX2, 
SOX9, MSX2 OCN, and ALP, mRNA levels were abrogated 
(Figure 3D). Chetomin abolished upregulation of RUNX2 
protein expression induced by hypoxia (5% O2, 12 hours; 
Figure 3E). In addition, chetomin inhibited hypoxia-mediated 
increase in OCN in the ECM (day 15; Figure 3F) and ECM 
calcification (day 10; Figure 3G). These results suggest that 
HIF-1 activity plays a role in hypoxia-mediated osteochon-
drogenic differentiation and ECM calcification of VSMCs.
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The Involvement of ROS in Hypoxia-Mediated 
HIF-1α Upregulation, Osteochondrogenic 
Differentiation, and ECM Calcification of VSMCs
There is a complex interplay between ROS production and 
hypoxia in which hypoxia increases ROS production, and ex-
cess ROS production increases HIF-1α expression. Therefore, 
next we examined the role of this interplay between ROS and 
HIF-1 in the hypoxia-driven osteochondrogenic differentia-
tion and ECM calcification of VSMCs.
To see whether hypoxia influences intracellular ROS pro-
duction VSMCs were kept under normoxia (21% O2, 4 hours) 
or hypoxia (5% O2, 4 hours) followed by monitoring of ROS 
Figure 1. Hypoxia induces osteochondrogenic differentiation of vascular smooth muscle cells (VSMCs). Confluent VSMCs (passage 5–8) were maintained under 
normoxic (N, 21% O2) or hypoxic (H, 5% O2) conditions or exposed to the hypoxia mimetic drugs CoCl2 (CC, 200 μmol/L), desferrioxamine (DFO, 20 μmol/L), bipyridyl 
(BP, 100 μmol/L). A, HIF (hypoxia-inducible factor)-1α, Glut-1 (glucose transporter 1), and β-actin protein expressions detected by Western Blot from whole cell lysate 
(12 h). Representative Western blots from 3 independent experiments. Densitometry analysis (mean±SD) of 3 independent experiments. B, VEGFA (vascular endo-
thelial growth factor A) levels (48 h, mean±SD) were determined from cellular supernatant by ELISA in triplicates from 4 independent experiments. C, Relative mRNA 
expressions (6 h, mean±SD) of VEGFA, GLUT1, RUNX2, SOX9, MSX2, OCN, ALP normalized to GAPDH from 3 independent experiments performed in triplicates. 
D, RUNX2 (runt-related transcription factor 2), SOX9 (Sry-related HMG box-9), ALP (alkaline phosphatase), and β-actin protein expressions detected by Western Blot 
from whole cell lysate (12 h, 3 d, 6 d). Representative Western blots from 3 independent experiments. Densitometry analysis (mean±SD) of 3 independent exper-
iments. E, Alkaline phosphatase activity (mean±SD) of VSMCs measured in triplicates from 4 independent experiments (12 h, 3 d, 6 d). F, OCN (osteocalcin) level in 
EDTA-solubilized ECM samples (mean±SD) assessed by ELISA from 4 independent experiments. P values were calculated using 1-way ANOVA followed by Dunnett 
post hoc analysis in A and B and Student t test in D, E, and F. *P<0.05, **P<0.01, ***P<0.005, ****P<0.001 when compared with control cells under normoxia.
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production over an additional 4-hour period. Compared with 
normoxic condition, hypoxia increased ROS production in 
VSMCs (Figure 4A). Hypoxia-driven elevation of ROS pro-
duction was abrogated by the broad ROS scavenger NAC (5 
mmol/L) and the H2O2 scavenger SP (5 mmol/L; Figure 4B). 
In contrast, the superoxide dismutase mimetic manganese (III) 
tetrakis (4-benzoic acid) porphyrin chloride (50 μmol/L) failed 
to inhibit hypoxia-mediated ROS production (Figure 4B). To 
investigate the source of ROS production under hypoxia we 
applied NADPH oxidase 1/4 inhibitor (GKT137831, GKT, 
20 μmol/L) and rotenone (5 μmol/L) that inhibits mitochon-
drial ROS formation. Rotenone reduced, whereas GKT had no 
effect on hypoxia-induced ROS production (Figure 4C). Then 
we tested the effect of NAC, SP, and rotenone on hypoxia-
induced upregulation of HIF-1α. All the 3 ROS scavengers 
inhibited hypoxia-induced elevation of HIF-1α expression (12 
hours; Figure 4D). These results suggested that ROS, and par-
ticularly H2O2, plays a role in hypoxia-driven increase in HIF-
1α expression. To further confirm the involvement of H2O2 
in the upregulation of HIF-1α, next we treated VSMCs with 
H2O2 (1, 10, 100 μmol/L, 30 minutes) and evaluated protein 
expression of HIF-1α. We found that H2O2 markedly induced 
the expression of HIF-1α in VSMCs (Figure 4E). Then, to 
address whether HIF-1 activation is required for hypoxia-
driven ROS production, we measured ROS production in 
VSMCs exposed to hypoxia (5%, 4 hours) in the presence or 
absence of chetomin (6 nmol/L). Chetomin completely abol-
ished hypoxia-mediated ROS formation (Figure 4F), suggest-
ing that HIF-1 activation is involved in hypoxia-driven ROS 
production in VSMCs.
Following this we investigated whether inhibition of ROS 
formation influences hypoxia-driven osteochondrogenic dif-
ferentiation and ECM calcification of VSMCs. We found 
that the ROS inhibitors NAC, SP, and rotenone attenuated 
hypoxia-mediated increases in mRNA levels of osteochon-
drogenic transcription factors, that is, RUNX2 and SOX9 (6 
hours) and diminished the hypoxia-driven upregulation of 
RUNX2 protein expression (12 hours; Figure 5A through 5C). 
In addition, we found that NAC, SP, and rotenone inhibited 
hypoxia-induced ECM calcification assessed by alizarin red 
staining (Figure 5D, day 10). Furthermore, calcium (day 10) 
and OCN (day 15) levels of ECM of hypoxia-treated VSMCs 
were largely attenuated by NAC, SP, and rotenone (Figure 5E 
and 5F). These results pointed out a fundamental role of ex-
cess ROS formation in HIF-1α upregulation as well as in the 
process of VSMC osteochondrogenic differentiation and sub-
sequent calcification under hypoxic conditions.
Hypoxia Induces Upregulation of RUNX2 in 
Mice Lung and Aorta In Vivo and Induces 
Calcification of Mice Aorta Ex Vivo
To investigate whether hypoxia induces osteochondrogenic 
reprogramming in vivo, we exposed C57BL/6 mice to hy-
poxia (10% O2) for 12, 24, and 48 hours. Lungs and aortas 
were harvested for analysis from hypoxia-exposed and control 
(21% O2) mice. As expected, hypoxia triggered upregulation 
of Glut-1 at 12 hours in the lung (Figure 6A). In addition, 
24-hour hypoxia exposure induced a 1.7-fold increase in 
RUNX2 mRNA expression in the lung (Figure 6B). Similarly 
to that of lung, Glut-1 mRNA was elevated in the aorta of 
hypoxia-treated mice at 12-hour time point (Figure 6C). We 
found persistent elevation (≈2- to 3-fold) of RUNX2 mRNA 
expression in the aorta at all time points compared with nor-
moxia controls (Figure 6D).
Recently, a novel organ culture model of aorta has been 
established to study VC.39 We used this approach to assess the 
effect of hypoxia on VC. We dissected aortas from C57BL/6 
mice and cultured under normoxic or hypoxic conditions. As 
positive control, we used osteogenic medium, supplemented 
with 2.5 mmol/L phosphate. After 6 days of culture, we deter-
mined Ca content of the aortas. Osteogenic medium triggered 
Figure 2.  Hypoxia induces extracellular matrix (ECM) calcification of 
vascular smooth muscle cells (VSMCs). Confluent VSMCs (passage 5–8) 
were maintained under normoxic (21% O2) or hypoxic (5% O2) conditions 
or exposed to osteogenic medium (supplemented with 2.5 mmol/L phos-
phate, 0.6 mmol/L Ca) for 10 days. A, Time course of Ca accumulation in 
ECM (mean±SD). Data derived from 3 independent experiments performed 
in triplicates. B, Representative alizarin red staining (day 10) and quantifi-
cation (mean±SD) of 3 independent experiments performed in duplicates 
(optical density [OD]). C, Cell viability determined after 10 days of treat-
ment. Mean±SD from 3 independent experiments performed in quadru-
plicates is shown. P values were calculated using 1-way ANOVA followed 
by Tukey multiple comparison analysis. **P<0.01, ***P<0.005, ****P<0.001 
when compared with control cells under normoxia, ##P<0.01, ###P<0.005 
in comparison between hypoxic and osteogenic conditions.
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a 7.6-fold increase in the Ca content of the cultured aortas 
when compared with control aortas. Importantly, we observed 
a 5.2-fold elevation in the Ca content of aortas cultured under 
hypoxic conditions when compared with normoxia controls 
(Figure 6E). We provided evidence that hypoxia-mediated el-
evation of ROS production and HIF-1 transcriptional activity 
are required for hypoxia-mediated osteogenic differentiation 
of VSMCs in vitro, therefore then we addressed whether ROS 
and HIF-1 activation plays a role in hypoxia-mediated aorta 
calcification ex vivo. Our results revealed that the ROS inhib-
itor NAC (5 mmol/L) as well as chetomin (6 nmol/L) attenu-
ated hypoxia-mediated aorta calcification ex vivo (Figure 6F).
Discussion
For decades, cardiovascular calcification was considered as a 
passive degenerative process in which calcium and phosphate 
accumulates in the form of hydroxyapatite in different places 
of the cardiovascular system. By now this paradigm changed 
and it became broadly accepted that cardiovascular calcifica-
tion is a highly regulated process sharing many features with 
embryonic bone formation.40 Osteochondrogenic differentia-
tion of certain cells in the cardiovascular system is considered 
to be the major cellular mechanism of VC.14,41,42 Numerous 
inducers and inhibitors of such osteochondrogenic differenti-
ation have been identified to date.43
VC was observed in various diseases associated with sys-
temic or local hypoxia. For example, examination of post-
mortem lungs in a case-control study revealed that bronchial 
artery calcification occurs in patients with asthma, and the ex-
tent of calcification was related to the duration of the disease.6 
Accelerated coronary artery calcification was observed in 
patients with chronic obstructive pulmonary disease as well, 
that was strongly correlated with low arterial blood oxygena-
tion.7,44 VC is a characteristic feature of atherosclerosis,45 and 
Figure 3.  Hypoxia triggers osteochondrogenic differentiation of vascular smooth muscle cells (VSMCs) through HIF (hypoxia-inducible factor)-1. Confluent 
VSMCs (passage 5–8) were maintained under normoxic (N, 21% O2) or hypoxic (H, 5% O2) conditions in the presence or absence of the HIF-1 inhibitor chet-
omin (Chet/C, 6 nmol/L). A, Relative mRNA expressions (6 h, mean±SD) of VEGFA (vascular endothelial growth factor A) and GLUT1 (glucose transporter 1) 
normalized to GAPDH from 3 independent experiments performed in triplicates. B, VEGFA levels (48 h, mean±SD) were determined from cellular supernatant 
by ELISA in triplicates from 3 independent experiments. C, Glut-1 and β-actin protein expressions detected by Western Blot from whole cell lysate (12 h). 
Representative Western blots from 3 independent experiments. Densitometry analysis (mean±SD) of 3 independent experiments. D, Relative mRNA expres-
sions (6 h, mean±SD) of RUNX2 (runt-related transcription factor 2), SOX9 (Sry-related HMG box-9), MSX2 (Msh Homeobox 2), OCN (osteocalcin), and ALP 
(alkaline phosphatase) normalized to GAPDH from 3 independent experiments performed in triplicates. E, RUNX2 and β-actin protein expressions detected 
by Western Blot from whole cell lysate (12 h). Representative Western blots from 3 independent experiments. Densitometry analysis (mean±SD) of 3 inde-
pendent experiments. F, OCN protein in EDTA-solubilized ECM samples (day 15, mean±SD) measured by ELISA in triplicates from 3 independent experi-
ments. G, Representative alizarin red staining (day 10) and quantification (mean±SD) of 3 independent experiments performed in duplicates (optical density 
[OD]). P values were calculated using 1-way ANOVA followed by Tukey multiple comparison analysis. *P<0.05, **P<0.01, ***P<0.005 when compared with 
control cells under normoxia, #P<0.05, ##P<0.01, ###P<0.005 in comparison of hypoxia vs hypoxia+chetomin groups.
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intimal spotty calcification frequently associates with intra-
plaque neovascularization, a hallmark of plaque hypoxia.46 
Plaque hypoxia contributes to atheroma evolution, remodel-
ing and vulnerabilization through diverse mechanisms but the 
question whether hypoxia is directly linked to atherosclerotic 
plaque calcification has not been addressed.47–50
Because hypoxia is a common denominator in dis-
eases associated with VC here we investigated whether hy-
poxia per se triggers osteochondrogenic differentiation of 
VSMCs. Our study provides evidence that hypoxia induces 
osteochondrogenic reprogramming and subsequent ECM cal-
cification of VSMCs. We describe the critical role of HIF-1 ac-
tivation and ROS in the osteochondrogenic effect of hypoxia.
Different cells of the cardiovascular system can undergo 
osteochondrogenic differentiation.14,41,42 Here, we focused on 
human aortic VSMCs, because it is the most extensively studied 
in vitro model of VC, and osteochondrogenic differentiation 
of these cells is critically involved in arterial calcification. We 
found that hypoxia induced stabilization of HIF-1α and ele-
vated the expressions of hypoxia response genes, VEGFA and 
Figure 4.  Interplay between reactive oxygen species (ROS) production, HIF (hypoxia-inducible factor)-1α stabilization and HIF-1 activity. A–D, Confluent 
vascular smooth muscle cells (VSMCs) (passage 5–8) were exposed to hypoxia (H, 5% O2) in the presence or absence of different ROS scavengers; N-acetyl 
cysteine (NAC; 5 mmol/L), Mn(III)-tetrakis (4-benzoic acid) porphyrin chloride (MnTBAP; MTB, 50 μmol/L), sodium pyruvate (SP, 5 mmol/L), GKT (20 μmol/L), 
and rotenone (Rot, 5 μmol/L). A, Intracellular ROS production in VSMCs after a 4-hour exposure to normoxia or hypoxia. ROS was monitored for 4 h follow-
ing the exposure. Fold change over normoxia at 0 min is shown as mean±SD from 3 independent experiments. B, C, ROS production of VSMCs exposed to 
hypoxia (4 h) in the presence of NAC, MTB, SP, GKT, and Rot in comparison to normoxia control. ROS production (mean±SD, 3 h post-treatment) of 3 inde-
pendent experiments is shown. D, HIF-1α and β-actin protein expressions detected by Western Blot from whole cell lysate (12 h). Representative Western 
blots from 3 independent experiments. Densitometry analysis (mean±SD) of 3 independent experiments. E, HIF-1α and β-actin protein expressions detected 
by Western Blot from whole cell lysate of VSMCs (passage 7–8) exposed to H2O2 (30 min, 1–100 μmol/L). F, ROS production of VSMCs exposed to hypoxia 
(4 h) in the presence of chetomin (C, 6 nmol/L) in comparison to normoxia control. ROS production (mean±SD, 3 h post-treatment) of 3 independent experi-
ments is shown. P values were calculated using Student t test in A 1-way ANOVA followed by Tukey multiple comparison analysis in B–D and F or Dunnett 
post hoc analysis in E. *P<0.05, **P<0.01, ***P<0.005, ****P<0.001 when compared with control cells under normoxia. ##P<0.01, ###P<0.005 in comparison 
of hypoxia vs hypoxia+inhibitor groups.
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GLUT1 in VSMCs. Besides this response, hypoxia triggered 
an osteochondrogenic differentiation program characterized 
by upregulation of osteochondrogenic transcription factors 
and bone-specific proteins in VSMCs. Hypoxia-mediated 
switch of the osteochondrogenic reprogramming in VSMCs 
eventually led to elevated ECM calcification in vitro.
The effect of hypoxia on osteogenic capability was 
studied previously in diverse osseous and pluripotent mes-
enchymal cells. Park et al51 showed that hypoxia (2% O2) 
decreases the expressions of RUNX2, OCN, and ALP in 
MG63 osteoblast-like cells. In contrast, Salim et al52 found 
that hypoxia (2% O2) had little effect on osteogenic differ-
entiation of primary osteoblasts and mesenchymal precur-
sors, but short-term anoxic treatment inhibited in vitro bone 
nodule formation and calcium deposition in both cell types 
through downregulation of RUNX2. On the contrary Wagegg 
et al53 reported that hypoxia promotes osteogenesis of mul-
tipotent human mesenchymal stromal cells in an HIF-1 and 
RUNX2-dependent way. Ichijima et al54 showed that hypoxia 
Figure 5.  Reactive oxygen species (ROS) are involved in hypoxia-medi-
ated osteochondrogenic differentiation and extracellular matrix (ECM) 
calcification of vascular smooth muscle cells (VSMCs). Confluent VSMCs 
(passage 5–8) were exposed to hypoxia (H, 5% O2) in the presence or ab-
sence of different ROS scavengers; N-acetyl cysteine (NAC; 5 mmol/L), 
sodium pyruvate (SP, 5 mmol/L), and rotenone (Rot, 5 μmol/L). A, B, Rela-
tive mRNA expressions (6 h, mean±SD) of RUNX2 (runt-related transcrip-
tion factor 2) and SOX9 (Sry-related HMG box-9) normalized to GAPDH 
from 3 independent experiments performed in triplicates. C, RUNX2 and 
β-actin protein expressions detected by Western Blot from whole cell ly-
sate (12 h). Representative Western blots from 3 independent experiments. 
Densitometry analysis (mean±SD) of 3 independent experiments. D, Rep-
resentative alizarin red staining (day 10) and quantification (mean±SD) of 
3 independent experiments performed in duplicates (optical density [OD]). 
E, Ca level of HCl-solubilized ECM samples (day 10, mean±SD) from 3 
independent experiments. F, OCN (osteocalcin) level in EDTA-solubilized 
ECM samples (day 15, mean±SD) assessed by ELISA from 3 independent 
experiments. P values were calculated using 1-way ANOVA followed by 
Tukey multiple comparison analysis. **P<0.01, ***P<0.005 when compared 
with control cells under normoxia. #P<0.05, ##P<0.01, ###P<0.005 in 
comparison of hypoxia vs hypoxia+inhibitor groups.
Figure 6.  Hypoxia induces osteochondrogenic reprogramming in mice 
lung and aorta. A–D, C57BL/6 mice were exposed to hypoxia (10% O2) 
for 12, 24, or 48 h (N=6, each time points). Control mice were exposed 
to normoxia (N=6). Relative mRNA expressions (mean±SD) of GLUT1 
(glucose transporter 1) and RUNX2 (runt-related transcription factor 2) 
normalized to cyclophilin A in lung and aorta. E, F, Cleaned whole aortas 
from C57BL/6 mice were cultured ex vivo under normoxic (N, n=5), hy-
poxic (Hyp, n=5), and osteogenic (Osteo, n=5) conditions for 6 days. In 
a separate experiment aortas were cultured under hypoxic conditions in 
the presence of N-acetyl cysteine (NAC; 5 mmol/L) or chetomin (Chet; 
6 nmol/L; n=5 per group). Ca content of aortas normalized to wet aorta 
weight (mean±SD). P values were calculated using 1-way ANOVA followed 
by Dunnett post hoc analysis in A–E and Tukey multiple comparison anal-
ysis in F. *P<0.05, **P<0.01, ***P<0.005 when compared with normoxia 
controls. ##P<0.01 in comparison of hypoxia vs hypoxia+inhibitor groups.
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induced osteogenesis of periosteal cells. Regarding smooth 
muscle cells, Mokas et al21 showed that hypoxia enhances 
phosphate-mediated osteogenic differentiation and calcifica-
tion of VSMCs.
These results suggest that hypoxia regulates osteogenic 
differentiation in a highly sensitive and a cell-specific manner. 
Considering that RUNX2 is the master regulator of osteogenic 
differentiation, the high variability of the hypoxia responses 
described in diverse cells could be at least partially explained 
by the differences in RUNX2 promoter activity in osseous and 
nonosseous cells.55
Cellular and systemic homeostatic response to hypoxia is 
regulated by the HIF-1 pathway. HIF-1 is a heterodimer basic 
helix-loop-helix-PAS domain transcription factor, composed 
of an oxygen-sensitive α subunit (HIF-1α) and a stable β sub-
unit.18 Under normoxia, HIF-1α is constantly synthesized and 
degraded, while under hypoxia, HIF-1α is stable and dimer-
izes with the β subunit.18 The heterodimer translocate into 
the nucleus, binds to cis-acting hypoxia response elements 
in HIF-1 target genes, recruits coactivator molecules, that is, 
p300 and CREB-binding protein, and the complex activates 
transcription.18 Here we showed that inhibition of the HIF-1 
pathway abolished hypoxia-mediated osteochondrogenic 
differentiation of VSMCs, suggesting that HIF-1 activation 
is critically involved in the osteochondrogenic effect of hy-
poxia. Our results are in strong agreement with the work of 
Ruffenach et al22 in which they showed that overexpression of 
HIF-1α promotes, whereas adenovirus expressing a dominant 
negative form of HIF-1α inhibits calcification of pulmonary 
artery smooth muscle cells. These findings are also supported 
by the previous clinical observation that HIF-1α plasma lev-
els significantly and independently predict the presence of 
coronary artery calcification in patients with type 2 diabetes 
mellitus.19
Recent evidence suggests a complex interplay between 
HIF-1 and RUNX2 in the regulation of osteogenic differentia-
tion. Our results revealed that hypoxia induces the expression 
of RUNX2, which effect was dependent on HIF-1 activity. On 
the other hand Mokas et al21 showed that induction of RUNX2 
by elevated phosphate leads to HIF-1α stabilization. In addi-
tion, Ruffenach et al22 showed that overexpression of RUNX2 
triggers HIF-1α activation. In the recent years, regulation of 
RUNX2 through the epigenetic reader BRD4 (bromodomain 
protein 4) has been established. BRD4 induces RUNX2 tran-
scription in cancer cells.56 BRD4 expression is elevated in 
lungs, distal pulmonary arteries, pulmonary artery smooth 
muscle cells, and coronary arteries of patient with pulmonary 
arterial hypertension, that contributes to vascular remodeling 
and the development of coronary artery disease.57,58 Inhibition 
of BRD4 has been shown to reverse hypoxia-induced pulmo-
nary arterial hypertension57 and suppress VC in a hypercholes-
terolemic mice model.59
Although it sounds paradoxical, hypoxia stimulates ROS 
production in diverse mammalian cells.60 Studies showed 
that mitochondrial electron transport chain complexes I and 
III and NADPH oxidases are involved in hypoxia-mediated 
increase in ROS production.60–63 Moreover, the finding that 
mitochondria-targeted antioxidants abolish the hypoxia re-
sponse proved that mitochondrial ROS production is essential 
for propagation of the hypoxic signal toward the activation of 
the HIF pathway.64
Based on this evidence we hypothesized that hypoxia-
mediated elevation of mitochondrial ROS production could 
critically participate in hypoxia-mediated osteochondrogenic 
differentiation of VSMCs. In line of this notion here we con-
firmed that hypoxia triggers elevated ROS production in 
VSMCs. Inhibition of ROS production with NAC and the mi-
tochondrial complex I inhibitor rotenone abolished hypoxia-
induced HIF-1α stabilization and inhibited hypoxia-induced 
upregulations of RUNX2, SOX9, and OCN and attenuated 
calcification.
Previous studies already suggested a causative role of ex-
cessive ROS production in cardiovascular pathophysiology 
including VC.32–34 Osteogenic differentiation of VSMCs has 
been linked to enhanced ROS production, and vascular cells 
expressing osteogenic markers were identified as sources of 
excess ROS around calcifying foci.33 Importantly, Zhao et 
al34 showed that inhibition of mitochondrial ROS generation 
attenuates phosphate-mediated osteogenic differentiation of 
VSMCs. Byon et al65 showed that hydrogen peroxide promotes 
osteogenic differentiation of VSMCs through the induction of 
RUNX2. In agreement with these findings here we showed 
that hypoxia-mediated production of hydrogen peroxide plays 
an essential role in the stabilization of HIF-1α and in the pro-
motion of osteochondrogenic response in VSMCs. We found 
that hydrogen peroxide is sufficient to stabilize HIF-1α under 
normoxic condition in VSMCs which is in agreement with 
previous observations.28,66
Inhibition of HIF-1 stabilization by ROS scavengers under 
hypoxic conditions suggests that ROS generation is upstream 
of HIF-1 stabilization in VSMCs under hypoxia, as has been 
described in many other experimental conditions and recog-
nized as hypoxia/ROS/HIF-1 axis.31,67
Interestingly, we also found that inhibition of HIF-1 ac-
tivity abolished hypoxia-mediated ROS production, sug-
gesting a more complex interplay between ROS generation 
and HIF-1 activity. A similar phenomenon was described in 
a previous study, in which decreased ROS production was 
observed in heterozygous HIF-1α deficient mice upon hy-
poxia exposure.68 The authors suggested that once HIF-1 is 
activated, it may function to maintain increased ROS levels 
and they proposed a positive feed-forward loop between ROS 
and HIF-1 activity.68 This might be implicated in our experi-
mental settings, which needs to be further investigated.
Hypoxia and accelerated arterial calcification coincide in 
diverse diseases such as asthma, chronic obstructive pulmo-
nary disease, and obstructive sleep apnea.6–8 Here we showed 
that hypoxia upregulates RUNX2 expression in mice lung 
and aorta in vivo. In addition, using an ex vivo organ culture 
approach we showed that hypoxia triggers Ca accumulation 
in mouse aorta in an HIF-1–dependent and ROS-dependent 
manner.
To conclude, data reported in the present study suggest 
that hypoxia is an independent factor sufficient to trigger 
osteochondrogenic differentiation of VSMCs. We propose 
that unfettered generation of ROS during hypoxia may be the 
signal switching on the osteochondrogenic differentiation pro-
gram of VSMCs that leads eventually to VC.
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Highlights
• Hypoxia induces osteochondrogenic differentiation and extracellular matrix calcification in vascular smooth muscle cells.
• HIF-1 (hypoxia-inducible factor 1) activation is involved in hypoxia-mediated osteochondrogenic differentiation and extracellular matrix calci-
fication in vascular smooth muscle cells.
• Hypoxia elevates mitochondrial reactive oxygen species formation in vascular smooth muscle cells, which is indispensable in hypoxia-driven 
osteochondrogenic differentiation of vascular smooth muscle cells.
• Hypoxia induces osteochondrogenic reprogramming in the mouse aorta.
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